SCHEMBL15065919

SCHEMBL15065919

O=C(C=Cc1cc(NC(=O)c2cccnc2)ccc1Oc1cccc(Cl)c1)NO

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.53
▸ MEN1 O00255 3/20 0.53
▸ GRM5 P41594 4/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CSF1R P07333 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ LMNA P02545 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ KDR P35968 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15065917 1.00 KMT2A (0.53) KMT2AMEN1GRM5SMN1; SMN2L3MBTL1
SCHEMBL15068419 0.89 SMN1; SMN2 (0.48) KMT2AMEN1SMN1; SMN2L3MBTL1TSHR
SCHEMBL15065392 0.89 NPC1 (0.58) KMT2AMEN1SMN1; SMN2L3MBTL1NPC1
SCHEMBL15065389 0.89 NPC1 (0.58) KMT2AMEN1SMN1; SMN2L3MBTL1NPC1
SCHEMBL15068422 0.89 SMN1; SMN2 (0.48) KMT2AMEN1SMN1; SMN2L3MBTL1TSHR
SCHEMBL15068379 0.85 KMT2A (0.52) KMT2AMEN1SMN1; SMN2L3MBTL1TSHR
SCHEMBL15068380 0.85 KMT2A (0.52) KMT2AMEN1SMN1; SMN2L3MBTL1TSHR
SCHEMBL15088591 0.83 HDAC4 (0.52) KMT2AMEN1NPC1LMNAMAPT
SCHEMBL15066665 0.83 HDAC4 (0.52) KMT2AMEN1NPC1LMNAMAPT
SCHEMBL15065367 0.82 LMNA (0.51) KMT2AMEN1TSHRCYP2C9MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150045367-A1 CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 PHARMACYCLICS LLC 2015-02-12 — — US claimed
EP-2797875-A1 CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 Pharmacyclics, Inc. (US) 2014-11-05 — — EP claimed
WO-2013101600-A1 CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 PHARMACYCLICS, INC. (US) 2013-07-04 — — WO claimed
US-20150045367-A1 CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 PHARMACYCLICS LLC 2015-02-12 — — US disclosed
EP-2797875-A1 CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 Pharmacyclics, Inc. (US) 2014-11-05 — — EP disclosed
WO-2013101600-A1 CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 PHARMACYCLICS, INC. (US) 2013-07-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045367-A1 CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 HDAC8, HDAC5, HDAC7 KMT2A 91/4885MEN1 2526/4885GRM5 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback